ECMO therapy, a corner stone in the management of severe COVID-19 ARDS, increases inflammatory markers like WBC, IL-6, IL-10, and tumor necrosis factor (TNF)-alpha due to activation of inflammatory and coagulation pathways caused by the constant contact of cellular and humoral blood components on the large extracorporeal surface (9). This evidence concerns the gene TNF and acute respiratory distress syndrome.